AWMSG – A vision for the future

John Watkins

AWMSG - Overview

- Technology Appraisal
- Oversight, direction and influence of medicines management and safety
- •Process:- liaison with industry, NMG, Steering committee to public meeting
- Decision making process
 NMG advice, public debate, private vote, cf. NICE process
- Advisory to Cabinet Secretary at Welsh Government

Lower health benefits, higher costs: do not recommend

Greater health benefits,
higher costs:
unable to recommend,
need a cost-utility analysis
(STA)

Difference in overall health benefit

Difference in costs

Lower health benefits, lower costs:

unable to recommend, need a cost-utility analysis (STA)

Similar/greater health benefits, similar/lower costs: recommend as an option




Language of Technology Appraisal

- Clinical Effectiveness
- Cost Effectiveness
- QALYs
- Incremental Cost Effectiveness Ratios
- Comparators/standard of care
- Progression Free survival
- Overall Survival
- Networked Meta Analysis
- Intractable names of pharmaceutical medicines
- Orphan and Ultra Orphan
- •End of Life Criteria



Impact of Treatment




Courtesy Stephen Monaghan

Oh that life were so simple

Evidence base

- -Small studies
- -Immature data
- -Surrogate end points
- -Lack of comparator arm
- -Wrong Comparator
- -Point estimates of effectiveness, HRs etc.



Economic Evaluation






Figure 6. OS output






Other Challenges


- Changes in Payment systems for Appriasals
- Cancer Drugs Fund
- Patient access schemes and discounts
- Increasing commercial in confidence discussions
- Time horizons for advice
- Double standards we treat new therapies by a different standard to old
- Personalised medicine and what does that mean
- Making sense of combination therapies e.g. adjuvants, drugs etc.












Source: - Santa Fe Institute



Towards Complexity in Health and Healthcare

- •Which dose?
- •Which combination?
- •What dosage combination?
- •Are long term responders different?





Broader role for AWMSG

Greater cooperation with other groups

Drugs and therapeutics committees

HTW

HEIW

National Clinical Audit

PHW

NICE

Scotland and Northern Ireland TACs

- •Greater role in CPD of health professionals by providing help, advice and insight using vehicles such as WeMeRec, National Audits, Prescribing indicators, CASPA
- •Greater role and higher profile in health advocacy and public awareness

Today's Programme

Thank you